State-of-the-Art Speakers

Paul I. Terasaki State-of-the-Art Lecture

Sponsored by the Paul I. Terasaki Research Fund

Immune Management of the Transplant Recipient

Monday, June 1, 2020 ● 10:15 am – 10:45 am

 
Allan D. Kirk, MD, PhD

David C. Sabiston, Jr. Distinguished Professor and Chair
Department of Surgery
Vice Dean for Surgical Disciplines
Duke University School of Medicine

Surgeon-in-Chief
Duke University Health System

Editor-in-Chief
American Journal of Transplantation

Allan D. Kirk received his MD and PhD in Immunology from Duke University, where he also completed his surgery residency. He completed a multiorgan transplant fellowship at the University of Wisconsin, during which time he began his longstanding work on costimulation blockade and personalized immune management. He advanced this work as Chief of Transplant Research for the Armed Services Transplant Service in Washington, DC, and subsequently as Chief of the intramural organ transplant program at the National Institutes of Health.  In 2007, he moved to Emory University, as Vice Chair for Surgical Research, and in 2014, was appointed Chairman of the Department of Surgery at Duke University.  He holds Professorships in Surgery, Pediatrics and Immunology and serves as Surgeon-in-Chief for the Duke University Health System.

In addition to his clinical transplant practice, he has published over 300 scientific manuscripts, and continues NIH-, DoD- and FDA-sponsored investigations in organ transplantation and immune management.  He has focused increasingly on the curation and analysis of multidimensional data for use in Real World Evidence trial design, clinical decision support tool development and drug discovery.

He has served as the Editor-in-Chief of the American Journal of Transplantation since 2010, is a member of the AST and ASTS, and is an elected member of the National Academy of Medicine.


Thomas A. Starzl State-of-the-Art Lecture

Tuesday, June 2, 2020 ● 10:15 am – 10:45 am

Carl June, MD

Director, Center for Cellular Immunotherapies

Director, Parker Institute for Cancer Immunotherapy

Professor of Pathology and Laboratory Medicine

Carl June is a physician scientist and the Richard W. Vague Professor in Immunotherapy at the Perelman School of Medicine at the University of Pennsylvania in the Departments of Medicine and Pathology and Laboratory Medicine. He is the director of the Center for Cellular Immunotherapies at the Perelman School of Medicine, and the Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania. June has published more than 500 manuscripts and is the recipient of numerous prizes and honors, including election to the Institute of Medicine in 2012 and the American Academy of Arts and Sciences in 2014. He is the scientific founder of Xcyte Therapies Inc. and Tmunity Therapeutics. CTL019, the CAR T cell developed in the June laboratory was the first gene therapy to be approved by the US FDA in August 2017. The therapy developed by Dr. June’s team is now approved and marketed by Novartis in the US,  Europe and Japan.